William Faubion
Mayo Clinic
Appearances
- DateMay 7, 2023Over the past decade, big data and artificial intelligence (AI) have become standard concepts in digestive disease research, both as individual tools and applied together…
Moderators
Yale School of MedicineMayo Clinic - DateMay 6, 2023State of the art - omic methods now provide deeper insight into the biologic architecture of IBD. This session will review state of the art advances in metabolomics, transcriptomics, and epigenetics in defining the biologic basis of IBD…
Presenter
Mayo Clinic - DateMay 8, 2023Aconitate decarboxylase 1 (ACOD1; also known as IRG-1) is the ubiquitous source of the metabolite itaconate, which dampens inflammasome activation by preventing HIF1α production of IL-1β and prevents TNF production through NRF2 activation…
- DateMay 7, 2023SOCIETY: DDW
Presenter
Mayo Clinic - DateMay 18, 2024The risk of bowel surgery in patients with Inflammatory Bowel Disease (IBD) and Clostridioides difficile infection (CDI) can change rapidly over the course of the disease…
Presenter
Speakers
- DateMay 21, 2024Introduction: The molecular mechanism by which effector CD4+ T helper (Th) cells remain activated to possibly mediate resistance to biologics and consequent refractory human inflammatory bowel disease (IBD) is not clear…
Presenter
Speakers
- DateMay 19, 2024BACKGROUND: Loss of the suppressive function of helper T regulatory cells (Tregs) can promote uncontrolled inflammation in Crohn’s Disease (CD)…
- DateMay 21, 2024BACKGROUND: Darvadstrocel (DVS), a suspension of expanded allogeneic adipose-derived mesenchymal stem cells, is approved for the treatment of complex Crohn’s perianal fistulas (CPF)…
- DateMay 20, 2024BACKGROUND: Immune activation by immune checkpoint inhibitors (ICI) has shown promise in the treatment of diverse cancer types at the cost of different immune-related adverse events (irAEs)…
Presenter
Mayo ClinicSpeakers
Mayo ClinicMayo Clinic, RochesterMayo ClinicMayo Clinic - DateMay 19, 2024BACKGROUND: Tofacitinib and upadacitinib are JAK inhibitors (JAKi) approved for Inflammatory Bowel Disease (IBD) treatment. Response rates to JAKi in IBD are varied, and there are concerns for serious side effects like venous thromboembolism, cancer and cardiovascular events…
Presenter
- DateMay 19, 2024BACKGROUND: The pathogenesis of Inflammatory Bowel Disease (IBD) is a multifactorial process characterized by inflammation and damage to the intestinal barrier, which is made up of intestinal epithelial cells (IECs)…